MediLink Dosed 1st Patient in Phase I Study with ADC YL202

MediLink Therapeutics today announced that the first patient has been successfully dosed with its Antibody Drug Conjugate (ADC) product YL202 in the United States and the first dose was well tolerated without any adverse events (AEs) observed. This is a multi-center nonrandomized, open-label, first-in-human phase I study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated Non-small cell lung cancer (NSCLC) or hormone receptor (HR)-positive and HER2-negative breast cancer (BC). “The initiation of this study represents a significant milestone for MediLink Therapeutics, as it marks the second program of our ADC platform to enter the clinic in less than one year”, stated Tony Xue, PhD, Chairman, Founder & CEO.

2023-02-14Learn more

ADC treatment for cancer, how to take the future path

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of highly cytotoxic drugs, effectively delivering the drug payload to tumor sites and potentially reducing the severity of side effects. They are often referred to as the "magic bullets" of cancer therapy.

2023-06-17Learn more

Pricing of ADC Drugs

​In the US market, the most expensive priced ADC drug is Pfizer's Bebosan (ocetuzumab), with an annual treatment cost of $290,000 for a 60kg patient, equivalent to nearly 2 million Chinese yuan (CNY 1.95 million). The next highest priced ADC is GSK's Blenrep, priced at 1.36 million yuan. These two are the only ADC drugs priced over one million yuan.

2023-06-05Learn more

Information on some ADC listed drugs

Who is KADCYLA for? Early Breast Cancer KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery. Patients are selected for therapy based on an FDA-approved test for KADCYLA

2023-04-21Learn more

Jiangsu Public TV visit MediLink

2022-10-28Learn more

FDA Clearance of IND Application for YL202

September 3, 2022 - MediLink Therapetutics announced that YL202 has been cleared for its IND application by the U.S. Food and Drug Administration for Phase I first-in-human study

2022-09-03Learn more

1st patient dosed with product YL201 in the United States

2022-04-23Learn more

MediLink Therapeutics closes US$70 million Series B financing

SUZHOU, China, March 14, 2022 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) recently announced completion of a US$70 million Series B financing. This round was led by LYFE Capital and Qiming Venture Partners, and co-invested by Legend Capital, Loyal Valley Capital and Highlight Capital (HLC), etc. The new funding will support clinical development of MediLink's new generation Antibody-Drug Conjugate (ADC) pipeline, as well as early discovery and development of novel conjugated drugs.

2022-04-14Learn more